Home » Stocks » CKPT

Checkpoint Therapeutics, Inc. (CKPT)

Stock Price: $2.40 USD -0.11 (-4.38%)
Updated May 10, 2021 4:00 PM EDT - Market closed
Market Cap 194.74M
Revenue (ttm) 165,000
Net Income (ttm) -26.31M
Shares Out 70.30M
EPS (ttm) -0.41
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 10
Last Price $2.40
Previous Close $2.51
Change ($) -0.11
Change (%) -4.38%
Day's Open 2.54
Day's Range 2.35 - 2.55
Day's Volume 833,361
52-Week Range 1.56 - 5.38

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Meme penny stocks are a budding sector; have you heard of these 4? The post 4 Meme Penny Stocks To Watch As DogeCoin Rises appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStock...

Other stocks mentioned: BTU, EARS, EBON
1 day ago - PennyStocks

NEW YORK, May 06, 2021 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results fo...

4 days ago - GlobeNewsWire

Investors in penny stocks know the prices of many have crashed. But these seven stocks may have room to run higher.

Other stocks mentioned: AGRX, AQMS, CATB, HEPA, IFRX, LLNW
1 month ago - InvestorPlace

NEW YORK, March 09, 2021 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results ...

2 months ago - GlobeNewsWire

Members include preeminent clinical and scientific thought leaders in oncology Members include preeminent clinical and scientific thought leaders in oncology

2 months ago - GlobeNewsWire

NEW YORK, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero...

4 months ago - GlobeNewsWire

NEW YORK, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced updated interim res...

6 months ago - GlobeNewsWire

NEW YORK, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company focused on the acquisition, developm...

6 months ago - GlobeNewsWire

NEW YORK, Sept. 17, 2020 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint” or the “Company”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announce...

7 months ago - GlobeNewsWire

NEW YORK, Sept. 17, 2020 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced updated interim ...

7 months ago - GlobeNewsWire

Following up on a prior interview on the status of its leading immunotherapy product candidate, cosibelimab, Benzinga spoke with Checkpoint Therapeutics President and CEO James Oliviero about the progre...

7 months ago - Benzinga

NEW YORK, Aug. 17, 2020 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James F. Oli...

8 months ago - GlobeNewsWire

NEW YORK, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company focused on the acquisition, develo...

9 months ago - GlobeNewsWire

NEW YORK, July 27, 2020 (GLOBE NEWSWIRE) --  Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that an abstract...

9 months ago - GlobeNewsWire

- U.S. patent protection through at least May 2038 - Registration-enabling study of cosibelimab in cutaneous squamous cell carcinoma over one-third enrolled

1 year ago - GlobeNewsWire

CKPT expects to submitt a BLA for cosibelimab in 2021.

1 year ago - Seeking Alpha

NEW YORK, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that feedback fro...

1 year ago - GlobeNewsWire

NEW YORK, Nov. 20, 2019 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the pricing of it...

1 year ago - GlobeNewsWire

NEW YORK, Nov. 19, 2019 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it is propos...

1 year ago - GlobeNewsWire

NEW YORK, Nov. 08, 2019 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (Checkpoint) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that new pharmacoki...

1 year ago - GlobeNewsWire

NEW YORK, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immuno-oncology biopharmaceutical company focused on the acquisition, develop...

1 year ago - GlobeNewsWire

NEW YORK, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immuno-oncology biopharmaceutical company focused on the acquisition, develop...

1 year ago - GlobeNewsWire

NEW YORK, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immuno-oncology biopharmaceutical company focused on the acquisition, develop...

1 year ago - GlobeNewsWire

NEW YORK, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage, immuno-oncology biopharmaceutical company focused on the acquisition, develo...

1 year ago - GlobeNewsWire

Checkpoint Therapeutics, Inc. (CKPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

2 years ago - Zacks Investment Research

About CKPT

Checkpoint Therapeutics, Inc., a clinical-stage immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to programmed death ligand-1 (PD-L1) and blocks the PD-L1 interaction with the programmed death receptor-1 and B7.1 receptors; and CK-302, a human agonistic antibody that is designed to bind to and trigger... [Read more...]

Industry
Biotechnology
IPO Date
Jun 26, 2017
Stock Exchange
NASDAQ
Ticker Symbol
CKPT
Full Company Profile

Financial Performance

In 2020, CKPT's revenue was $1.07 million, a decrease of -37.41% compared to the previous year's $1.71 million. Losses were -$23.08 million, -6.61% less than in 2019.

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for CKPT stock is "Strong Buy." The 12-month stock price forecast is 15.25, which is an increase of 535.42% from the latest price.

Price Target
$15.25
(535.42% upside)
Analyst Consensus: Strong Buy